Biocept appoints Antonino Morales as President and CEO; Riccitelli resigns

BIOCEPT INC

Samuel D. Riccitelli resigned as Interim President and CEO and from Board, effective June 16, 2023.
Antonino Morales appointed President and CEO; continues as CFO and Board member.
Morales' base salary increased from $400K to $470K; target bonus raised from 40% to 50%.
Robert Walsh promoted to VP, Controller and principal accounting officer.
Walsh, a CPA, joined Biocept in May 2022; previously at PwC and CFGI.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed (interim)

Samuel D. Riccitelli

Interim President and Chief Executive Officer

BIOCEPT INC

Effective: 2023-06-16
Successor: Antonino Morales
Filed: June 21, 2023, 7:59 PM ET

On June 16, 2023, Samuel D. Riccitelli resigned from his position as Interim President and Chief Executive Officer of Biocept, Inc. (the “Company”), and from the Company’s Board of Directors (the “Board”), effective June 16, 2023.

Role change

Robert Walsh

Vice President, Controller and principal accounting officer

BIOCEPT INC

Effective: 2023-06-16
Filed: June 21, 2023, 7:59 PM ET

On June 16, 2023, Robert Walsh, the Company’s Controller, was promoted to Vice President, Controller and principal accounting officer.

Appointed

Antonino Morales

President and Chief Executive Officer

BIOCEPT INC

Effective: 2023-06-16
Filed: June 21, 2023, 7:59 PM ET

On June 16, 2023, the Board appointed Antonino Morales as the Company’s President and Chief Executive Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Samuel D. Riccitelli resigned as Interim President and Chief Executive Officer at BIOCEPT INC.

Action: resigned
Role: Interim President and Chief Executive Officer

Exact text from the filing

On June 16, 2023, Samuel D. Riccitelli resigned from his position as Interim President and Chief Executive Officer of Biocept, Inc. (the “Company”), and from the Company’s Board of Directors (the “Board”), effective June 16, 2023.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Robert Walsh changed role as Vice President, Controller and principal accounting officer at BIOCEPT INC.

Action: promoted
Role: Vice President, Controller and principal accounting officer

Exact text from the filing

On June 16, 2023, Robert Walsh, the Company’s Controller, was promoted to Vice President, Controller and principal accounting officer.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Antonino Morales was appointed as President and Chief Executive Officer at BIOCEPT INC.

Action: appointed
Role: President and Chief Executive Officer

Exact text from the filing

On June 16, 2023, the Board appointed Antonino Morales as the Company’s President and Chief Executive Officer.

View on SEC.gov

Source: SEC EDGAR

accession 0001193125-23-171148

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.